RxDoctor Payments Data

Sean Liu

Infectious Disease · New York, NYNPI 1780959023

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Boston Scientific. That places this record below the midpoint for infectious disease clinicians in NY, where the typical reported total is $190.

$113in general payments, 2019–2025

Across 1 payment — averaging $113.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$113
$1,400,780in research payments, 2019–2025

Across 72 payments — averaging $19,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.3M
  • Grifols, S.A.$98K

What the payments were for

  • Food & beverage$113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific1$113

How this compares

$113 in reported general payments places this provider in the 40th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$21,145
Medicare patients
68
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →